Intersect ENT, Inc. (XENT): Price and Financial Metrics
XENT Price/Volume Stats
| Current price | $28.24 | 52-week high | $28.25 |
| Prev. close | $28.24 | 52-week low | $15.92 |
| Day low | $28.23 | Volume | 837,100 |
| Day high | $28.25 | Avg. volume | 351,526 |
| 50-day MA | $27.80 | Dividend yield | N/A |
| 200-day MA | $27.27 | Market Cap | 954.91M |
XENT Stock Price Chart Interactive Chart >
Intersect ENT, Inc. (XENT) Company Bio
Intersect ENT provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company was founded in 2003 and is based in Menlo Park, California.
Latest XENT News From Around the Web
Below are the latest news stories about Intersect ENT Inc that investors may wish to consider to help them evaluate XENT as an investment opportunity.
Teleflex (TFX) Q4 Earnings and Revenues Surpass EstimatesTeleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
TransMedics (TMDX) Reports Q4 Loss, Tops Revenue EstimatesTransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Havens Advisors Llc Buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Sells , ,New York, NY, based Investment company Havens Advisors Llc (Current Portfolio) buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Rogers Corp, Triple-S Management Corp, sells , , , Cloudera Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Havens Advisors Llc. |
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource UtilizationMENLO PARK, Calif., January 25, 2022--Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization |
Intersect ENT, Inc. (NASDAQ:XENT) Expected to Announce Quarterly Sales of $37.13 MillionAnalysts expect that Intersect ENT, Inc. (NASDAQ:XENT) will post sales of $37.13 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Intersect ENTs earnings, with estimates ranging from $36.53 million to $37.82 million. Intersect ENT reported sales of $28.23 million in the same quarter last year, which would [] |
XENT Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 4.36% |
| 5-year | 58.12% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | 19.26% |
| 2020 | -8.03% |
| 2019 | -11.64% |
Continue Researching XENT
Want to see what other sources are saying about Intersect ENT Inc's financials and stock price? Try the links below:Intersect ENT Inc (XENT) Stock Price | Nasdaq
Intersect ENT Inc (XENT) Stock Quote, History and News - Yahoo Finance
Intersect ENT Inc (XENT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...